Literature DB >> 17006269

Bilateral renal metastases from osteosarcoma: A case report and review of the literature.

Luís Henrique Toshihiro Sakamoto1, Wellington Mendes, Marcela Pecora, Rodrigo Guimarães Andrade, Maria Dirlei Ferreira Begnani, Beatriz de Camargo.   

Abstract

Improvements in multimodal therapy for osteosarcoma (OS) have increased event-free and overall survival. But have also led to a greater number of recurrences in uncommon sites. We report a young adult with OS who developed late bilateral renal relapse. Late recurrences to the kidneys have a more aggressive clinical behavior and poor prognosis documented by 15 cases of OS metastastic to the kidney in the literature. Two of those patients had a long survival after chemotherapy and surgery. This suggests that the disease can be controlled with early detection and treatment.

Entities:  

Mesh:

Year:  2006        PMID: 17006269     DOI: 10.1097/01.mph.0000212961.73844.fc

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  4 in total

1.  Metastatic osteosarcoma to the liver and the kidney: a case report and review of the literature.

Authors:  Wen-Xi Yu; Yang Yao
Journal:  BMJ Case Rep       Date:  2009-02-26

2.  Bilateral calcified renal metastases from osteosarcoma.

Authors:  Sameer Vyas; Naveen Kalra; Rakesh Kapoor; Vanita Suri; Niranjan Khandelwal
Journal:  Cancer Imaging       Date:  2010-05-08       Impact factor: 3.909

3.  Renal metastases of a femur osteosarcoma: a case report and a review of the literature.

Authors:  Yousra Akasbi; Samia Arifi; Karim Lahlaidi; Tarik Namad; Nawfel Mellas; Mohammed Jamal El Fassi; My Hassan Farih; Afaf Amarti; Omar El Mesbahi
Journal:  Case Rep Urol       Date:  2012-02-28

4.  Biological characterization of preclinical Bioluminescent Osteosarcoma Orthotopic Mouse (BOOM) model: A multi-modality approach.

Authors:  Rama Garimella; Jeff Eskew; Priyanka Bhamidi; George Vielhauer; Yan Hong; H Clarke Anderson; Ossama Tawfik; Peter Rowe
Journal:  J Bone Oncol       Date:  2013-02       Impact factor: 4.072

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.